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Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylyl Cyclase Activating Peptide
(PACAP) are regeneration-associated neuropeptides, which are up-regulated by
neurons following peripheral nerve injury. So far, they have only been studied for
their roles as autocrine signals for both neuronal survival and axon outgrowth during
peripheral nerve regeneration. In this report, we examined VIP and PACAP’s paracrine
effects on Schwann cells and macrophages in the distal nerve stump during peripheral
nerve regeneration. We show that VPAC1, VPAC2, and PAC1 are all up-regulated in the
mouse distal nerve following peripheral nerve injury and are highly expressed in Schwann
cells and macrophages within the distal sciatic nerve. We further investigated the effect
of VIP and PACAP on cultured rat Schwann cells, and found that VIP and PACAP can not
only promote myelin gene expression in Schwann cells but can also inhibit the release
of pro-inflammatory cytokines by Schwann cells. Furthermore, we show that VIP and
PACAP inhibit the release of pro-inflammatory cytokines and enhance anti-inflammatory
cytokine expression in sciatic nerve explants. Our results provide evidence that VIP
and PACAP could have important functions in the distal nerve stump following injury to
promote remyelination and regulate the inflammatory response. Thus, VIP and PACAP
receptors appear as important targets to promote peripheral nerve repair following injury.
Keywords: VIP and PACAP, receptor expression, Schwann cells, macrophages, remyelination, inflammatory
cytokines
INTRODUCTION
The peripheral nervous system has a remarkable ability to regenerate following injury and the
up-regulation of regeneration-associated genes in neurons contributes significantly to the success
of repair following injury (Navarro et al., 2007; Ma and Willis, 2015). Neuropeptides such as
galanin, neuropeptide Y, Vasoactive Intestinal Peptide (VIP), and Pituitary Adenylyl Cyclase
Activating Peptide (PACAP) are important regeneration-associated neuropeptides for peripheral
nerve regeneration (Navarro et al., 2007; Waschek, 2013). VIP is a 28 amino acid peptide, first
isolated from porcine intestine, which has the ability to induce vasodilation in the canine femoral
artery (Said and Mutt, 1970, 1972). PACAP is a 38 amino acid peptide and was discovered
some years later, sharing 68% homology at the N-terminus with VIP (Miyata et al., 1989).
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Subsequent studies have revealed that both VIP and PACAP are
widely distributed peptide hormones with a variety of biological
activities by acting as neurotransmitters in many different
organs and tissues (Harmar et al., 1998). Three receptors,
named as VPAC1, VPAC2, and PAC1, have been identified for
the VIP and PACAP ligands. Both VIP and PACAP can act
through VPAC1 and VPAC2 whereas PAC1 selectively binds
PACAP. These receptors are G-protein coupled receptors with
seven transmembrane domains and the binding of VIP and
PACAP to these receptors typically activates Gs and Gq/11
proteins and increases both intracellular cyclic AMP (cAMP) and
inositol1,4,5-trisphosphate/diacylglycerol levels in target cells
(Harmar et al., 1998; Castorina et al., 2014).
Many studies have reported that both VIP and PACAP
are dramatically up-regulated in motor and sensory neurons
after peripheral nerve injury (Zhou et al., 1999; Xiao et al.,
2002; Armstrong et al., 2003). VIP mRNA induction in motor
neurons is detectable 6 h after peripheral nerve injury and
reaches a maximum up-regulation on day 7. Thereafter, the
level decreases slightly but VIP expression remains high up
to 30 days following injury (Armstrong et al., 2003). cDNA
microarray analysis in DRG (dorsal root ganglion) at 2, 7, 14,
and 28 days following injury also showed at least a 10 fold
VIP up-regulation at all investigated timepoints (Xiao et al.,
2002). The up-regulation of PACAP mRNA in motor neurons
is also detectable 6 h after injury but PACAP peaks at 48 h
with more than a 20-fold up-regulation. PACAP levels then
decrease slightly from day 2 following injury, but remain more
than 10-fold elevated for as long as 30 days during regeneration
(Zhou et al., 1999). Previous studies have confirmed that VIP
and PACAP are secreted by regenerating axons (Reimer et al.,
1999), and upon release it can promote neuronal survival and
axon outgrowth via receptors localized to the growth cone of
regenerating axons (Lioudyno et al., 1998; Zhou et al., 1999;
Armstrong et al., 2003, 2008). Reports also showed that both
VIP and PACAP are up-regulated in sympathetic neurons after
peripheral nerve injury, but the up-regulation is not as strong
as seen in motor and sensory neurons (Zhou et al., 1999;
Armstrong et al., 2003).
So far, all studies have focused on the autocrine effect of VIP
and PACAP on neuronal survival and axon outgrowth during
peripheral nerve regeneration (Armstrong et al., 2003; Navarro
et al., 2007). However, the question remains unanswered as to
why neurons dramatically up-regulate VIP and PACAP ligands
and yet down-regulate their receptors, if the effects of VIP and
PACAP are purely upon on regenerating axons (Zhou et al.,
1999; Waschek et al., 2000). It is well known that large numbers
of macrophages infiltrate into the distal nerve stump during
peripheral nerve regeneration (Martini et al., 2008), and both
VIP and PACAP have well characterized immunomodulatory
functions on macrophages in other tissues to regulate pro- and
anti-inflammatory factor expression (Delgado et al., 1999; Ganea
and Delgado, 2002). There is also some evidence to show that
VIP and PACAP have a direct effect on cultured Schwann cells
and schwannoma cells to promote cell survival, induce laminin
synthesis as well as regulating myelin protein expression (Zhang
et al., 1996; Castorina et al., 2008, 2014; Lee et al., 2009).
Given the large amount of VIP and PACAP ligand released by
the growth cone of regenerating axons and the down-regulation
of VIP and PACAP receptors in neurons, we hypothesized that
VIP and PACAP could have important paracrine effects upon
Schwann cells and macrophages in the distal nerve stump to
promote peripheral nerve regeneration. Therefore, in this work,
we examined VPAC1, VPAC2, and PAC1 mRNA expression
following mouse sciatic nerve transection injury and found
that all three receptors are up-regulated in both Schwann
cells and macrophages within the distal nerve stump. Next,
we took in vitro approaches and investigated the effects of
VIP and PACAP on cultured primary rat Schwann cells and
mouse sciatic nerve explants. Our studies showed that VIP
and PACAP could not only promote myelin gene expression in
Schwann cells but also inhibited the release of pro-inflammatory
cytokines by Schwann cells. Furthermore, we showed that
VIP and PACAP inhibited the release of pro-inflammatory
cytokines and promoted anti-inflammatory cytokine expression
in sciatic nerve explants. Thus, our findings indicate that VIP
and PACAP have important paracrine effects in the distal nerve
stump to promote remyelination and resolve the peripheral
nerve inflammatory response in order to restore nerve tissue
homeostasis following repair.
MATERIALS AND METHODS
Animals and Peripheral Nerve Surgery
All work involving animals was carried out according to Home
Office regulation under the United Kingdom Animals (Scientific
Procedures) Act 1986. Ethical approval for all experiments
was granted by the University of Plymouth Animal Welfare
and Ethical Review Board. Sprague Dawley rats and C57BL/6
mouse breeding pairs were purchased from Charles River United
Kingdom Ltd. PLP-GFP mice were described before (Mallon
et al., 2002; Dun et al., 2019). All animals were housed in
a controlled laboratory environment (temperature 22 ± 2◦C,
humidity 50–60%, 12-h light/dark cycle). All animals were fed
with standard rodent diet and water ad libitum. Two month
old male and female mice were randomized. Total animals
used for each experiment were stated in the figure legends. For
sciatic nerve transection injury, mice were anesthetized with
isoflurane, the right sciatic nerve was exposed and transected
at approximately 0.5 cm proximal to the nerve trifurcation site
and no re-anastamosis of the severed nerve was performed.
Overlying muscle was sutured and the skin was closed with
an Autoclip applier. All animals undergoing surgery were
given appropriate post-operative analgesia, 0.05% bupivacaine
solution, topically applied above the muscle suture before
applying the surgical clip. Meloxicam (5 mg/kg) injection
was given just before recovery from anesthetic. All animals
undergoing surgery were given nesting material and enrichment
in the cage to prevent autotomy. All animals under surgery
were monitored daily. At the indicated time points post-
surgery for each experiment described, animals were euthanased
humanely by CO2 in accordance with United Kingdom Home
Office regulations.
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VIP, PACAP and Receptor Selective
Agonists, cAMP, PolyI:C and LPS
Vasoactive Intestinal Peptide (Catalog No.: 1911) and VPAC2
selective agonist (Catalog No.: Bay 55-9837) were purchased from
TOCRIS. PACAP38 (Catalog No.: H-8430), VPAC1 selective
agonist (Catalog No.: H-5802), and PAC1 selective agonist
Maxadilan (Catalog No.: H-6734), VPAC2 selective antagonist
(Catalog No.: H-7292), and PAC1 selective antagonist M65
(Catalog No.: H-6736), were purchased from Bachem. cAMP
(Catalog No.: D0627), PolyI:C (Catalog No.:P0913), and LPS
(Catalog No.: L3024) were purchased from Sigma.
Primary and Secondary Antibodies
Primary antibodies against VIP (Abcam, ab78536), PACAP
(Abcam, ab216627), VPAC1 (Santa Cruz, sc-30019; Abcam,
ab123517), VPAC2 (Santa Cruz, sc-30020), PAC1 (Santa Cruz,
sc-30018), myelin protein zero (Mpz) (Sigma, SAB2500665),
myelin basic protein (Mbp) (Abcam, ab40390), neurofilament
heavy chain (NF) (Abcam, ab4680), F4/80 (Abcam, ab6640), and
GAPDH (EMD Millipore, MAB374) were used. Hoechst and
species specific secondary antibodies conjugated with Alexa Fluor
488 or 568 dyes were purchased from Invitrogen. Horseradish
peroxidase conjugated secondary antibodies for western blotting
were purchased from Sigma.
Schwann Cell Culture and Sciatic Nerve
Explants
Schwann cells were prepared from sciatic nerve and brachial
plexus of nine postnatal day 3 Sprague Dawley rats as previously
described (Brockes et al., 1979; Dun et al., 2019). Schwann cells
were cultured in low glucose (1 g/ml) DMEM containing 3%
fetal bovine serum (FBS), 10 ng/ml NRG-1 (R&D, Cat No. 396-
HB-050), and 2 µM forskolin (Sigma, Cat No. 344270). Intact
sciatic nerve or distal sciatic nerve 10 day after transection injury
were dissected out in L15 medium, the epineurium was removed
under the dissection microscope and the nerves were slightly
teased in L15 medium, subsequently, teased nerve segments were
incubated with VIP, PACAP or receptor selective agonists in low
glucose (1 g/ml) DMEM containing 5% FBS.
Immunohistochemistry and
Immunocytochemistry
Sciatic nerve and DRG samples were dissected out and fixed
overnight in 4% paraformaldehyde (in PBS, PH7.2) at 4◦C.
Samples were then washed in PBS (3 × 10 min) and dehydrated
in 30% sucrose (in PBS) overnight at 4◦C. Subsequently, samples
were embedded in OCT medium and sectioned on a cryostat at
a thickness of 12 µm. Sections were permeabilized with 0.25%
Triton X-100 plus 1% bovine serum albumin (BSA) in PBS
for 45 min and then blocked with blocking buffer (3% BSA
plus 0.05% Triton X-100 in PBS) for 1 h at room temperature.
Sections were incubated with primary antibodies (1:100 diluted
in blocking buffer) overnight at 4◦C. The next day, sections
were washed with PBS (3 × 10 min) and then incubated with
species-specific secondary antibodies plus Hoechst dye (1:500
diluted in blocking buffer) for 1 h at room temperature. Finally,
sections were washed with PBS (3 × 10 min) and mounted with
Citifluor (Agar Scientific, R1320) for imaging with a Leica SP8
confocal microscope.
Western Blot
Nerve samples were directly sonicated into 1 X SDS
loading buffer. Cells were lysed in an appropriate volume
of radio-immunoprecipitation assay (RIPA) buffer (50 mM
Tris–HCl, pH 7.4, 0.1% SDS, 1% NP-40, 150 mM NaCl,
1 mM ethylenediaminetetraacetic acid (EDTA), 0.5% sodium
deoxycholate) and phosphatase inhibitor cocktails used at 1:100
(Santa Cruz Biotechnology, sc-45045 and sc-45065) on ice,
then spun down at 16,000 × g for 15 min at 4◦C. Supernatant
was transferred to new 1.5 ml microcentrifuge tubes and the
protein concentration was determined using the PierceTM BCA
Protein Assay Kit. An appropriate volume of sample containing
20 µg of protein was added to 4X sample buffer. Proteins were
separated on 10% or 12% SDS polyacrylamide running gels and
transferred onto a polyvinylidene fluoride (PVDF, 0.45 µm)
transfer membrane using the wet transfer method. Membranes
were blocked in 5% fat free milk in TBST (Tris buffered saline
plus 0.1% Tween-20) for 1 h at room temperature. Primary
antibodies were diluted (1:500) in 5% milk (in TBST) and the
membranes was incubated in primary antibodies overnight at
4◦C. Next day, membranes were washed in TBST (3 × 10 min)
and then incubated with HRP conjugated secondary antibody
(1:5000 in 5% milk, TBST) for 1 h at room temperature. After
three TBST washes (10 min each), Pierce ECL western blotting
substrate was added onto the membrane and incubated for
5 min to develop the chemiluminescent signal. Amersham
HyperfilmTM ECL films were used to capture the intensity of the
chemiluminescent signal. Exposed films were then developed
in a Compact X4 automatic processor. The intensity of protein
bands was quantified using the free ImageJ software available
from https://imagej.nih.gov/ij/.
mRNA Purification, cDNA Synthesis,
RT-PCR and qRT-PCR
Total mRNA was extracted using a miRNeasy Mini Kit
(Qiagen, 217004) and first stand cDNA was synthesized with
M-MLV reverse transcriptase (Promega, M368) using random
hexamer primers (Promega, C1181). RT-PCR was performed
in the G-Storm GS4M, qRT-PCR was performed in the PCR
LightCycler480 Real-Time PCR Instrument (Roche Applied
Science) using SYBR Green I Master with primers showing
in Table 1. Cross point (Cp) values were calculated by using
the software of the LightCycler480 Real-Time PCR Instrument.
Relative mRNA levels were calculated by the 2[-Delta Delta
C(T)] method (Livak and Schmittgen, 2001) using GAPDH as a
reference gene for normalization. All reactions were carried out
in triplicate for statistical analysis.
Statistical Analysis
Samples for Western blotting and qRT-PCR in Figures 1, 8 were
prepared by grouping three nerves from three different mice
together for each time point to create a pooled sample as n = 1,
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TABLE 1 | Primer sequences.
Primers Forward: 5′—3′ Reverse: 5′—3′ Accession numbers Size (bp)
Mouse VPAC1 GCCTCCACACAAGGCAAATG GTGTTTCCAGGTAGGGCACA NM_011703 160
Mouse VPAC2 ATAGGCGCGAGACTGAGGAA CAACCAGCAGTAGCAGGTCA NM_009511 135
Mouse PAC1 CCGGACCAAGTCTGGATGAC AGCCATCCTCAGTGCAGTTC NM_001025372 112
Mouse MCP-1 AGGTCCCTGTCATGCTTCTG TCTGGACCCATTCCTTCTTG NM_011333 249
Mouse TNFα CGTCAGCCGATTTGCTATCT CGGACTCCGCAAAGTCTAAG NM_013693 206
Mouse ILα GCAACGGGAAGATTCTGAAG TGACAAACTTCTGCCTGACG NM_010554 177
Mouse ILβ GCCCATCCTCTGTGACTCAT AGGCCACAGGTATTTTGTCG NM_008361 230
Mouse TNFγ ACTGGCAAAAGGATGGTGAC TGAGCTCATTGAATGCTTGG NM_008337 237
Mouse IL4 CCATATCCACGGATGCGACA AAGCACCTTGGAAGCCCTAC NM_021283 166
Mouse IL6 AGTTGCCTTCTTGGGACTGA TCCACGATTTCCCAGAGAAC NM_031168 159
Mouse IL10 GCTCTTGCACTACCAAAGCC CTGCTGATCCTCATGCCAGT NM_010548 112
Mouse IL13 GGCAGCATGGTATGGAGTGT CTTGCGGTTACAGAGGCCAT NM_008355 132
Mouse GAPDH AAGGTCATCCCAGAGCTGAA CTGCTTCACCACCTTCTTGA XM_017321385 222
Rat VPAC1 GCTCCTTAAAACTGGCCCCT TCAAACACCTCAGTGCCGTT NM_012685 149
Rat VPAC2 GAAGGCAGAGAGGGCGATAG CAACCAGCAGTAGCAGGTCA NM_017238 152
Rat PAC1 AGCATTCACCCCCTTTCCTCA GGAGAGAAGGCGAATACTGTGT NM_001270579 175
Rat MCP-1 CAGGTCTCTGTCACGCTTCT GGCATTAACTGCATCTGGCTG NM_031530 87
Rat TNFα CATCCGTTCTCTACCCAGCC AATTCTGAGCCCGGAGTTGG XM_008772775 151
Rat ILα CCTCGTCCTAAGTCACTCGC GGCTGGTTCCACTAGGCTTT NM_017019 105
Rat ILβ GACTTCACCATGGAACCCGT GGAGACTGCCCATTCTCGAC NM_031512 85
Rat IL6 AGCGATGATGCACTGTCAGA GGAACTCCAGAAGACCAGAGC NM_012589 106
Rat Krox20 AGGAGCAAATGATGACCGCC CATGCCATCTCCAGCCACTC NM_053633 185
Rat Mbp TGTGGGGGTAAGAGAAACGC AAGGTCGGTCGTTCAGTCAC NM_001025291 126
Rat Mpz ATGACCGAGGACCAATGACG CTGTGCTCCAGAGTGGTCAG NM_017027 102
Rat GAPDH AGTGCCAGCCTCGTCTCATA GGTAACCAGGCGTCCGATAC XM_017593963 77
and then repeated the process using another six animals to reach
n = 3. Therefore, we have used pooled biological replicates for
the repetition of these experiments. Statistical significance was
analyzed using the Student’s t-test and ANOVA by comparing the
test groups with the control groups. All data are represented in
the figures as mean value ± SEM. P values are indicated with
single asterisk (∗<0.05), double asterisks (∗∗<0.01) and triple
asterisks (∗∗∗<0.001) on graphs. Where graphs are not labeled
with an asterisk, any differences between the test groups and
the control groups were non-significant. The n number for each
experiment has been stated in each figure legend.
RESULTS
Up-Regulation of VPAC1, VPAC2 and
PAC1 in the Mouse Distal Nerve Stump
Following Transection Injury
We first used an RT-PCR method to detect expression of
VPAC1, VPAC2, and PAC1 mRNAs in the intact mouse sciatic
nerve and in the distal sciatic nerve stump 7 days following
transection injury. RT-PCR result showed that VPAC1, VPAC2,
and PAC1 mRNAs are all present in the intact mouse sciatic
nerve and are all seemingly increased in the distal nerve stump
following injury (Figure 1A). After confirming the presence of
their mRNAs in the intact sciatic nerve and in the distal sciatic
nerve stump, we used qRT-PCR to examine the time course
of their mRNA changes at 4, 7, 10, and 14 days following
sciatic nerve transection, using the contralateral intact sciatic
nerve as control. VPAC1, VPAC2, and PAC1 mRNA levels
are all significantly up-regulated in the distal nerve stump
following injury compared to their expression in control nerves
(Figure 1B). VPAC1 and VPAC2 show similar expression profiles
and their expression becomes significantly elevated compared to
control nerve at day 7 and peaks at day 10. PAC1 expression
is significantly up-regulated at day 4 and peaks at day 10.
Expression of VPAC1, VPAC2, and PAC1 begins to decrease at
day 14 but remains significantly increased compared to control
nerves (Figure 1B).
Next, we investigated changes in protein expression by
western blot in the proximal nerve stump and in the distal
nerve stump at 7, 10, and 14 days following transection injury.
Consistent with their mRNA up-regulation in the distal nerve
stump at day 7, 10, and 14, western blot results confirmed
the up-regulation of VPAC1, VPAC2, and PAC1 proteins in
the distal nerve stump at day 7, 10, and 14 post-injury
(Figures 1C–F). In contrast, there were no significant changes of
their protein levels in the proximal nerve stump following injury
(Figures 1C–F). Thus, our RT-PCR, qRT-PCR, and western blot
results not only confirmed the expression of VPAC1, VPAC2, and
PAC1 in the mouse distal nerve stump but also revealed their
up-regulation in the distal nerve stump following injury.
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FIGURE 1 | Up-regulation of VPAC1, VPAC2, and PAC1 following injury in the
mouse distal sciatic nerve. (A) RT-PCR showing the presence of VPAC1,
VPAC2, and PAC1 mRNAs in the intact (Con) mouse sciatic nerve and in the
distal sciatic nerve 7 days after transection injury. (B) qRT-PCR showing
VPAC1, VPAC2, and PAC1 mRNA up-regulation in the mouse distal sciatic
nerve at 4, 7, 10 and 14 days following transection injury, n = 3. (C) Western
blot showing VPAC1, VPAC2, and PAC1 protein expression in control
uninjured (C), proximal (P), and distal (D) mouse sciatic nerve at 7, 10, and
14 days following transection injury. (D–F) Quantification of VPAC1 (D),
VPAC2 (E), and PAC1 (F) protein levels from three independent western blot
results showing VPAC1, VPAC2, and PAC1 protein up-regulation in the distal
nerve stump. All samples were normalized to GAPDH and control samples
were normalized to 1. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001. (G–I) Double
staining of Vasoactive Intestinal Peptide (VIP) with the neuronal marker NeuN
showing that sensory neurons in the DRG express VIP at 7 days after sciatic
nerve transection injury. (J–L) Double staining of Pituitary Adenylyl Cyclase
Activating Peptide (PACAP) with the neuronal marker NeuN showing that
sensory neurons in the DRG express PACAP 7 days after sciatic nerve
transection injury. (M–O) Double staining of PACAP with neurofilament (NF)
(Continued)
FIGURE 1 | Continued
showing that PACAP is present in leading regenerating axons in the nerve
bridge 7 days after sciatic nerve transection injury. Scale bars in I and L
20 µm. Scale bar in O 40 µm. Thirty six mice were used in A and B for
RT-PCR and qPCR experiments. Twenty seven mice were used in C-F for
western blot experiments. Three mice were used in (G–O) for immunostaining
and three sections from each mouse were used for each staining.
Vasoactive Intestinal Peptide and PACAP are almost
undetectable in motor and sensory neurons of the adult
peripheral nervous system, but both are significantly up-
regulated after peripheral nerve injury (Zhou et al., 1999; Xiao
et al., 2002; Armstrong et al., 2003). The up-regulation of VIP
and PACAP in DRG tissue after peripheral nerve injury has
been very well documented using immunostaining, in situ
hybridization and microarray methodologies (Zhou et al.,
1999; Xiao et al., 2002; Armstrong et al., 2003). To confirm
VIP and PACAP up-regulation in sensory neurons of our
mouse sciatic nerve transection injury model, we stained VIP
and PACAP in sensory neurons of DRG tissue at 7 days after
sciatic nerve transection injury. Our staining has confirmed
that VIP and PACAP are expressed in sensory neurons of
DRG (Figures 1G–L). We also stained for PACAP in sciatic
nerve following injury and confirmed that PACAP is present
in regenerating axons (Figures 1M–O). Thus, VIP and PACAP
released from regenerating axons could interact with their
receptors expressed in the distal nerve stump during peripheral
nerve regeneration.
Expression Pattern of VPAC1, VPAC2 and
PAC1 in the Intact Mouse Sciatic Nerve
Our PCR and Western blot results have revealed VPAC1,
VPAC2, and PAC1 expression in intact mouse sciatic nerve. To
understand more clearly the cell-specific expression of VPAC1,
VPAC2, and PAC1 proteins in intact adult mouse sciatic nerve,
we performed VPAC1, VPAC2, and PAC1 double staining with
an axonal marker, NF, on adult sciatic nerve transverse sections.
Double staining of VPAC1 with NF showed that VPAC1 strongly
co-localized with NF (Figures 2A–C), indicating that VPAC1
is strongly expressed in axons of the peripheral nerve. VPAC1
also showed staining surrounding axons indicating that it is also
expressed in Schwann cells (Figures 2A–C). Similarly, double
staining of VPAC2 with NF showed that VPAC2 is expressed in
axons and Schwann cells (Figures 2D–F). In contrast, double
staining of PAC1 with NF showed that PAC1 is only expressed
in Schwann cells (Figures 2G–I). To confirm the expression of
VPAC1, VPAC2, and PAC1 in Schwann cells, we stained VPAC1,
VPAC2, and PAC1 on sciatic nerve transverse sections from
PLP-GFP mice, which label Schwann cells GFP-positive (Mallon
et al., 2002; Carr et al., 2017; Dun et al., 2019). Once again,
the staining showed that VPAC1 is high expressed in axons
and weakly expressed in Schwann cells (Figures 3A–I). VPAC2
staining shows stronger expression in Schwann cells than in
axons (Figures 3D–M). In contrast, PAC1 is only expressed in
Schwann cells with clear cell membrane localization comparing
to the cytoplasmic GFP signal (Figures 3G–I).
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FIGURE 2 | Double staining of VPAC1, VPAC2, and PAC1 with neurofilament
heavy chain (NF) on transverse sections from intact mouse sciatic nerve.
VPAC1 (A–C) and VPAC2 (D–F) staining both show co-localization with
neurofilament (NF) but PAC1 (G–I) does not. Yellow color in (C,F) shows
VPAC1 and VPAC2 co-localize with NF, respectively. VPAC1, VPAC2, and
PAC1 also show positive staining in areas surrounding axons. Scale bars in
(C,F,I) 20 µm. Three mice were used and three sections from each mouse
were stained for each receptor.
Expression Pattern of VPAC1, VPAC2,
and PAC1 in Mouse Distal Sciatic Nerve
Following Injury
Next, we transected the sciatic nerve in PLP-GFP mice to study
VPAC1, VPAC2, and PAC1 expression in Schwann cells of the
distal nerve stump. Immunostaining of VPAC1, VPAC2, and
PAC1 on transverse sections of distal nerve at 7 days post-injury
showed that all GFP positive cells express VPAC1, VPAC2, and
PAC1 receptors, confirming that VPAC1, VPAC2, and PAC1
are all still expressed in Schwann cells of the distal sciatic
nerve after transection injury (Figures 4A–I). Thus, VIP and
PACAP released from regenerating axons could interact with
their receptors that are expressed in Schwann cells of the distal
nerve stump to potentially regulate Schwann cell function during
peripheral nerve regeneration.
In addition to Schwann cells, macrophages are another
major cell type in the distal nerve stump following injury,
acting to promote peripheral nerve regeneration (Martini
et al., 2008; Stierli et al., 2018). VIP and PACAP have
well characterized functions in macrophages to promote anti-
inflammatory cytokine expression (Ganea and Delgado, 2002),
and studies in the immune system showed that macrophages
express both VIP and PACAP receptors (Delgado et al., 2004;
Vaudry et al., 2009). Therefore, we studied the expression of
VPAC1, VPAC2, and PAC1 in macrophages of the distal nerve
FIGURE 3 | VPAC1, VPAC2, and PAC1 staining on transverse sections from
uninjured sciatic nerve of PLP-GFP mice. VPAC1 (A–C), VPAC2 (D–F), and
PAC1 (G–I) staining all co-localize with GFP-positive Schwann cells. VPAC1
and VPAC2 also show positive staining in axons but PAC1 (G–I) does not.
Scale bars in (C,F,I) 20 µm. Three mice were used and three sections from
each mouse were stained for each receptor.
stump by immunohistochemistry on day 7 following mouse
sciatic nerve transection injury. Double staining of VPAC1,
VPAC2, or PAC1 with two well characterized macrophage
markers, F4/80 and CD68, on transverse sections revealed that
VPAC1 (Figures 5A–C,J–L) and PAC1 (Figures 5G–I,P–R)
are expressed by most macrophages of the distal nerve
stump and that some macrophages express also VPAC2
(Figures 5D–F,M–O, indicated by arrows). Thus, VIP and
PACAP released from regenerating axons could also interact
with receptors that are expressed in macrophages in the distal
nerve stump to regulate the immune response within the nerve
during regeneration.
VIP and PACAP Increase Myelin Protein
Expression in Cultured Schwann Cells
It has been previously been described that VIP and PACAP
treatment increases myelin protein expression in the rat RT4
schwannoma cell line (Castorina et al., 2014), but this has not
been tested in primary Schwann cells. Therefore, we studied
the effect of VIP and PACAP on myelin gene expression in
primary rat Schwann cells. First, the relative expression levels
in vitro of the three receptors was compared in primary rat
Schwann cells by qRT-PCR. This showed that VPAC1 has the
lowest expression, with VPAC2 expression 3.0 fold and PAC1
expression 10.4 fold higher compared to VPAC1 (Figure 6A).
Next, we investigated if VIP or PACAP treatment could induce
mRNA expression of three key markers of myelinating Schwann
cells, the transcription factor Krox20, Mpz, and Mbp in primary
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FIGURE 4 | VPAC1, VPAC2, and PAC1 expression in Schwann cells of the
distal nerve stump following injury. VPAC1, VPAC2, and PAC1 staining on
transverse sections from distal sciatic nerve of PLP-GFP mice 7 days after
transection injury. VPAC1 (A–C), VPAC2 (D–F), and PAC1 (G–I) all co-localize
with GFP in Schwann cells, confirming that VPAC1, VPAC2, and PAC1 are all
expressed in Schwann cells of the distal nerve stump. Scale bars in (C,F,I)
20 µm. Three mice were used and three sections from each mouse were
stained for each receptor.
rat Schwann cells. Schwann cells were treated with VIP or PACAP
(100 nM) every 24 h for 3 days with cAMP treatment used as
a positive control (Morgan et al., 1991; Monje et al., 2006). At
the mRNA level, both VIP and PACAP significantly increased the
expression of Krox20, Mpz, and Mbp (Figure 6F). This indicates
that both VIP and PACAP may function to induce remyelination
during peripheral nerve regeneration, however, PACAP appears
to have a much stronger ability than VIP in driving Krox20, Mbp,
and Mpz expression (Figure 6F). To investigate which receptor
may be responsible for promoting Schwann cell myelination,
Schwann cells were treated with VPAC1, VPAC2, and PAC1
specific agonists every 24 h for 3 days. All three receptor-specific
agonists significantly increased Krox20, Mbp, and Mpz mRNA
levels, indicating that this VIP and PACAP function in Schwann
cells may not be receptor specific (Figure 6G). However, selective
activation of PAC1 induced the biggest increase of Krox-20
and Mbp expression in Schwann cells (Figure 6G). We further
used western blotting and measured Mpz and Mbp protein
levels in Schwann cells after VIP, PACAP or VPAC1, VPAC2,
and PAC1 specific agonist treatment. This showed that VIP,
PACAP, VPAC1, VPAC2, and PAC1 specific agonists are all able
to increase Mpz and Mbp protein expression (Figures 6B–E).
The treatment showed that signaling through VPAC2 and PAC1
receptors has a much stronger ability to increase Mpz and
Mbp protein expression in Schwann cells (Figures 6B–E). Taken
together, both VIP and PACAP are able to induce Krox20, Mbp,
FIGURE 5 | Expression of VPAC1, VPAC2, and PAC1 in macrophages of the
mouse distal sciatic nerve at 7 days post-injury. (A–I) Double staining of
VPAC1, VPAC2, and PAC1 with macrophage marker F4/80 on transverse
sections from mouse distal sciatic nerve at 7 days post-transection injury.
(J–R) Double staining of VPAC1, VPAC2, and PAC1 with macrophage marker
CD68 on transverse sections from mouse distal sciatic nerve 7 days
post-transection injury. VPAC1 (A–C,J–L) and PAC1 (G–I,P–R) are expressed
in most macrophages of the distal nerve stump. Macrophages expressing
VPAC2 are indicated by arrows in (D–F,M–O). Scale bars 20 µm. Three mice
were used and three sections from each mouse were stained for each
receptor.
and Mpz expression in Schwann cells, while PACAP appears
to have a much stronger ability in promoting Krox20, Mbp,
and Mpz expression, and VPAC2 and PAC1 receptor are the
major receptors mediating their function in Schwann cells to
regulate myelination.
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FIGURE 6 | VIP and PACAP increase myelin gene expression in cultured Schwann cells. (A) Relative expression level of VPAC1, VPAC2, and PAC1 in cultured
primary rat Schwann cells, n = 3. (B,C) Western blot results show VIP, PACAP and receptor specific agonist up-regulation of myelin protein zero (Mpz) and myelin
basic protein (Mbp) protein expression in Schwann cells. (D,E) Quantification of Mpz and Mbp levels from three independent western blot results. (F) qRT-PCR data
showing VIP and PACAP increase the mRNA expression of myelinating Schwann cell markers Mbp, Mpz, and Krox20 after 24 h treatment, n = 3. (G) VPAC1,
VPAC2, and PAC1 receptor specific agonist treatment increases Mbp, Mpz, and Krox20 mRNA expression in Schwann cells. ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001.
VIP and PACAP Inhibit the Release of
Pro-inflammatory Cytokines in Schwann
Cells Induced by PolyI:C and LPS
After peripheral nerve injury, Schwann cells in the distal
nerve stump release pro-inflammatory cytokines such as tumor
necrosis factor α (TNFα), Interleukin 6 (IL6), Interleukin 1 alpha
(IL1α), Interleukin 1 beta (IL1β), and monocyte chemoattractant
protein-1 (MCP-1) to recruit macrophages for clearance of both
myelin and axonal debris (Martini et al., 2008; Zigmond and
Echevarria, 2019). Pro-inflammatory cytokine production has to
be carefully controlled in order to prevent excessive macrophage
recruitment. VIP and PACAP have well characterized functions
on macrophages to inhibit pro-inflammatory cytokine expression
(Ganea and Delgado, 2002). To study if VIP and PACAP
could inhibit pro-inflammatory cytokine expression in Schwann
cells, we used both polyinosinic-polycytidylic acid (PolyI:C) and
lipopolysaccharide (LPS) to induce pro-inflammatory cytokine
expression in primary rat Schwann cells. Schwann cells express
high levels of the toll-like receptors 3 and 4 (TLR3, TLR4),
and PolyI:C activates TLR3 while LPS activates TLR4 in
Schwann cells to induce pro-inflammatory cytokine expression
(Goethals et al., 2010).
As expected, PolyI:C (10 µg/ml) and LPS (100 ng/ml)
treatment significantly induced TNFα, IL6, IL1α, IL1β, and MCP-
1 expression in primary rat Schwann cells compared to untreated
Schwann cells (Figure 7A). VIP and PACAP treatment on un-
stimulated Schwann cells had no effect on TNFα, IL6, ILα, ILβ,
and MCP-1 expression (Figure 7A). Adding VIP or PACAP
together with PolyI:C and LPS significantly reduced the induction
of TNFα, IL6, ILα, ILβ, and MCP-1 by PolyI:C, and LPS in
Schwann cells (Figure 7A). In contrast, adding VPAC2 and
PAC1 receptor antagonists 1 h before VIP and PACAP treatment
inhibited this VIP and PACAP function (Figures 7B,C). To
investigate which receptors may be responsible for VIP and
PACAP inhibiting pro-inflammatory cytokine expression in
Schwann cells, Schwann cells were treated with receptor specific
agonists together with PolyI:C and LPS. qRT-PCR results showed
that VPAC1 and VPAC2 specific agonists significantly inhibited
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FIGURE 7 | VIP and PACAP inhibit pro-inflammatory cytokine expression in cultured Schwann cells. (A) VIP and PACAP inhibit Poly:IC and lipopolysaccharide (LPS)
induction of TNFα, IL6, ILα, ILβ, and MCP-1 expression in Schwann cells. (B) PAC1 receptor antagonist (M65) pre-treatment (1 h before adding PACAP) inhibits
PACAP function. (C) VPAC2 receptor antagonist pre-treatment (1 h before adding VIP and PACAP) inhibits VIP and PACAP function. (D) VPAC1 and VPAC2 receptor
specific agonist inhibits TNFα, IL6, ILα, ILβ, and MCP-1 expression in Schwann cells induced by PolyI:C and LPS stimulation. Note that PAC1 receptor specific
agonist inhibits IL6 and ILα but not TNFα, ILβ, and MCP-1 expression. All samples were normalized to GAPDH and control samples were normalized to 1. n = 4.
∗∗∗P < 0.001.
PolyI:C and LPS-induced TNFα, IL6, ILα, ILβ, and MCP-1
expression (Figure 7D), but a PAC1 specific agonist had no
effect (Figure 7D). Thus, VIP and PACAP appear to inhibit
pro-inflammatory cytokine expression through VPAC1 and
VPAC2 receptors on Schwann cells.
VIP and PACAP Inhibit the Release of
Pro-inflammatory Cytokines in Sciatic
Nerve Explants
Peripheral nerve injury rapidly triggers secretion of pro-
inflammatory cytokines such as TNFα, IL6, ILα, ILβ, and MCP-1
by Schwann cells in the distal nerve stump to recruit macrophages
for myelin and axonal debris clearance (Martini et al., 2008;
Zigmond and Echevarria, 2019). The pro-inflammatory cytokine
expression in the distal nerve peaks at 24 h following peripheral
nerve injury (Rotshenker, 2011). To test whether VIP and PACAP
could inhibit pro-inflammatory cytokine secretion in the injured
peripheral nerve, we used mouse adult sciatic nerve explants and
incubated with VIP and PACAP peptides. The nerve dissection
and explant culture triggers the injury response and induces
TNFα, IL6, ILα, ILβ, and MCP-1 secretion from Schwann cells
of the nerve explants (Figure 8A). After 24 h of VIP and
PACAP incubation, mRNA was extracted for subsequent qRT-
PCR analysis to measure TNFα, IL6, ILα, ILβ, and MCP-1
expression. qRT-PCR results showed that both VIP and PACAP
significant inhibited TNFα, IL6, ILα, ILβ, and MCP-1 expression
in sciatic nerve explants (Figure 8A). To determine which
receptor VIP and PACAP may be acting through to decrease pro-
inflammatory cytokine expression in the nerve explants, the same
experiments were performed but nerve explants were incubated
with receptor-specific agonists. Treatment with each receptor-
specific agonist showed that stimulation with VPAC1 and VPAC2
specific agonists significantly down-regulated the expression of
pro-inflammatory cytokines investigated (Figure 8B). Treatment
with a PAC1-specific agonist had no effect upon TNFα and
ILα expression (Figure 8B), but, to our surprise, the PAC1-
specific agonist significantly up-regulated IL6, ILβ, and MCP-1
expression in sciatic nerve explants (Figure 8B). As PACAP up-
regulation reaches its peak on day 2 following injury, which is
much earlier than the peak of VIP expression on day 7, the
regulation of IL6, ILβ, and MCP-1 by PACAP in nerve explants
indicates that PACAP may promote early pro-inflammatory
cytokine production in the sciatic nerve following injury. In line
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FIGURE 8 | VIP and PACAP regulate pro-inflammatory and anti-inflammatory
cytokine expression in nerve explants. (A) 24 h treatment with VIP or PACAP
inhibit TNFα, IL6, ILα, ILβ, and MCP-1 expression in cultured sciatic nerve
explants. Sciatic nerve explants were cultured from uninjured mouse sciatic
nerve. (B) 24 h treatment with VPAC1 or VPAC2 receptor-specific agonist
treatment inhibits TNFα, IL6, ILα, ILβ, and MCP-1 expression in cultured
sciatic nerve explants. In contrast, PAC1 receptor specific agonist treatment
induces IL6 and ILβ expression. Sciatic nerve explants were cultured from
uninjured mouse sciatic nerve. (C) 24 h treatment with VIP, PACAP or receptor
specific agonists induce anti-inflammatory cytokines IL4, IL10, and IL13
expression in nerve explants. Nerve explants were cultured from the distal
nerve stump at 10 days post-transection injury. All samples were normalized
to GAPDH and control samples were made relative to 1. n = 3. ∗∗P < 0.01,
∗∗∗P < 0.001. 27 mice were used in (A,B) for nerve explant culture, and 54
mice were used in (C) for nerve explant culture.
with above results for IL6, ILβ, and MCP-1 production in cultured
Schwann cells, VIP and PACAP appear to act through VPAC1
and VPAC2 receptors in Schwann cells in the nerve explants to
inhibit pro-inflammatory cytokine expression.
VIP and PACAP Enhance
Anti-inflammatory Cytokine Production
in Mouse Nerve Explants
Macrophages in the distal nerve stump secrete anti-inflammatory
cytokines such as IL4, IL10, and IL13 to promote peripheral nerve
regeneration (Martini et al., 2008; Ydens et al., 2012; Zigmond
and Echevarria, 2019). Macrophages infiltrate the injured nerves
from day 3 and the total macrophage number within the injured
nerve peaks between day 10 and day 14 post-injury and decreases
thereafter (Martini et al., 2008; Zigmond and Echevarria, 2019).
A previous study showed that 20.3% cells are macrophages
in the mouse distal sciatic nerve at 10 days following nerve
transection (Stierli et al., 2018). To investigate if VIP and
PACAP could act on mouse distal nerve and promote anti-
inflammatory cytokine expression, we treated nerve explants
taken from the distal nerve stump 10 days post-injury with
VIP and PACAP for 24 h and then investigated the expression
of anti-inflammatory cytokines IL4, IL10, and IL13. qRT-PCR
results showed that both VIP and PACAP are able to significantly
increase the expression of anti-inflammatory cytokines IL4, IL10,
and IL13 in distal nerve explants (Figure 8C). To determine
which receptor VIP and PACAP may be acting through to
increase IL4, IL10, and IL13 expression in the nerve explants,
we incubated the nerve explants with receptor specific agonists
and then measured the levels of IL4, IL10, and IL13 expression.
We found that VPAC1 and VPAC2 activation significantly up-
regulated the expression of IL4, IL10, and IL13. However, PAC1
stimulation only up-regulated IL13, it had no effect on IL10 and
IL4 expression (Figure 8C), indicating that VPAC1 and VPAC2
are the major receptors increasing anti-inflammatory expression
in the distal nerve explants.
DISCUSSION
Vasoactive Intestinal Peptide and PACAP are regeneration-
associated neuropeptides that are up-regulated in motor, sensory,
and sympathetic neurons following peripheral nerve injury (Xiao
et al., 2002; Armstrong et al., 2003; Navarro et al., 2007). Their
up-regulation in motor neurons is detectable 6 h after peripheral
nerve injury and both reach more than a 20-fold peak increase
(Zhou et al., 1999; Xiao et al., 2002; Armstrong et al., 2003).
Although previous studies have been focused upon studying
the autocrine effect of VIP and PACAP on neuronal survival
and axon outgrowth during peripheral nerve regeneration,
these studies have also revealed that the increase of VIP and
PACAP expression in neurons was accompanied by a decrease
in expression of their receptors (Zhou et al., 1999). For instance,
PAC1 mRNA expression was decreased to 50% in motor neurons
by 6 h after facial nerve axotomy comparing to uninjured site,
and by 1 week it had decreased to about 25%. Thereafter, the
level of PAC1 mRNA remained low at about 20–25% for up to
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30 days to the levels of control animal motor neurons (Zhou
et al., 1999; Waschek et al., 2000). The down-regulation of PAC1
has been explained as G protein-coupled receptor desensitization
in response to ligand binding (Zhou et al., 1999; Waschek
et al., 2000). Our new data reveals a plausible reason for the
receptor down-regulation in neurons, namely to allow VIP and
PACAP to execute their important function on Schwann cells
and macrophages in the distal nerve stump during regeneration.
Using qRT-PCR and western blot methods, we confirmed that
VPAC1, VAPC2, and PAC1 are all up-regulated in the distal
nerve stump after peripheral nerve injury. By using cell-specific
markers, we further showed that the receptor proteins are highly
expressed in Schwann cells and infiltrating macrophages of the
distal nerve stump.
Previous reports have shown that VPAC1, VPAC2, and PAC1
are expressed in cultured Schwann cells and schwannoma cells
(Zhang et al., 1996; Castorina et al., 2008, 2014; Lee et al.,
2009). Lee et al. (2009) compared VPAC1 and VPAC2 expression
levels in cultured Schwann cells and showed that Schwann cells
expressed higher levels of VPAC2 mRNA than VPAC1 mRNA. In
line with these findings, our results also showed that the VPAC2
mRNA level is 3 fold higher than VPAC1 mRNA expression
in Schwann cells. We also showed that PAC1 has the highest
level of expression in Schwann cells (Figure 8A). Zhang et al.
(1996) were the first to report a VIP function on Schwann cells.
They showed that VIP treatment on cultured primary Schwann
cells induced laminin synthesis (Zhang et al., 1996). More than
10 years later, Lee et al. (2009) published the second report
showing that VIP has a direct effect upon Schwann cells. Lee
et al. (2009) reported that VIP pre-treatment inhibited LPS-
induced nitric oxide (NO) synthase gene expression and NO
production in Schwann cells. In addition to these two papers
studying the direct effect of VIP on primary Schwann cells, two
other reports have shown that the schwannoma cell lines CRL-
2768 and RT4-P6D2T both express VPAC2 and PAC1 receptors
(Castorina et al., 2008, 2014). VIP and PACAP treatment on
rat RT4 schwannoma cells not only prevented cell apoptosis but
also induced myelin protein expression (Castorina et al., 2008,
2014). In vivo studies also showed that injection of VIP into the
mouse sciatic nerve gap following nerve transection and delivery
of VIP-expressing mesenchymal stem cells into a nerve guidance
conduit for rat sciatic nerve gap repair accelerated Schwann
cell re-myelination (Zhang et al., 2002; Hernandez-Cortes et al.,
2014). Binding of VIP and PACAP to their receptors increases
intracellular cAMP (Harmar et al., 1998; Castorina et al., 2014),
and cAMP is a key signaling molecule to induce Schwann
cell myelination during peripheral nerve development (Jessen
and Mirsky, 2005; Monk et al., 2009). Thus, VIP and PACAP
could be important signals to promote peripheral nerve re-
myelination during regeneration. Their effects on Schwann cell
re-myelination could be mediated by increase intracellular cAMP
levels. Previous studies also showed that binding of PACAP to
PAC1 had a much stronger ability to induce cAMP production
than binding to VPAC1 and VPAC2 receptors (Vaudry et al.,
2009). In light of this, then it is perhaps not surprising that
we observed PAC1 as the most effective at inducing Krox20,
Mbp, and Mpz expression in Schwann cells. Thus, it appears that
PACAP has more important role in Schwann cell re-myelination
although VIP does still apparently have the ability to promote
re-myelination during peripheral nerve regeneration.
After peripheral nerve injury, large numbers of macrophages
infiltrate into the distal nerve stump to clear axonal and
myelin debris; infiltrated macrophages also release pro-
inflammatory cytokines to recruit more macrophages to the
distal nerve (Ip et al., 2006; Zigmond, 2012; Zigmond and
Echevarria, 2019). The rapid inflammatory response after
peripheral nerve injury must be carefully controlled in order
to prevent excessive macrophage recruitment and unnecessary
inflammation and tissue damage. Currently, signals that are
required to balance the pro-inflammatory cytokines and
anti-inflammatory cytokines production in the distal nerve
stump have not been well studied (Martini et al., 2008). In
the later stages of regeneration, macrophages in the distal
nerve stump undergo a stage transition to completely down-
regulate pro-inflammatory cytokines production and further
up-regulate anti-inflammatory cytokines expression (Fry et al.,
2007). Again, signals that regulate macrophage stage transition
in the peripheral nerves during regeneration have not been
characterized. Staining on mouse distal nerve, at 7 days post-
injury, showed that macrophages within the distal nerve stump
express VPAC1, VPAC2, and PAC1. Incubation of distal nerve
explants, taken at 10 days post-injury, with VIP or PACAP for
24 h up-regulated anti-inflammatory cytokine IL4, IL10, and
IL13 expression. Thus, our studies have identified VIP and
PACAP as key signaling molecules to balance pro-inflammatory
and anti-inflammatory cytokine production and potentially
macrophage stage transition in the distal nerve stump. These
are key steps for the resolution of the inflammatory response
of the injured peripheral nerve and re-establishment of tissue
homeostasis. Indeed, a study in the PACAP knockout animals
not only showed that axon regeneration following injury
is reduced, but also found that pro-inflammatory cytokine
down-regulation is delayed and anti-inflammatory cytokine
production is impaired in the distal nerve stump following injury
(Armstrong et al., 2008).
Interestingly, the up-regulation of VIP and PACAP in neurons
was found to be regulated by cytokines present in the distal
nerve stump (Habecker et al., 2009; Zigmond, 2012). Given the
well characterized role of VIP and PACAP in macrophage stage
transition in other tissue and organs together with a large amount
of VIP and PACAP secretion by the regenerating axons to the
distal nerve stump, this implies a possible feedback mechanism
that, upon the up-regulation of pro-inflammatory cytokines in
the distal nerve stump, they not only recruit macrophages to
the distal nerve stump but also stimulate VIP and PACAP
secretion from neurons. Subsequently, VIP and PACAP act as
immunomodulators on infiltrating macrophages to balance pro-
inflammatory and anti-inflammatory cytokines production in the
distal nerve stump. In support of this idea, the time and the
peak of VIP expression not only coincides with macrophage
accumulation in the distal nerve stump during regeneration, but
also matches with the kinetics of IL-10 production (a classic anti-
inflammatory factor) in the distal nerve stump. IL-10 expression
starts to increase considerably in the distal nerve stump 4 days
post-injury, peaks at day 7 and remains elevated during the
course of regeneration (Be’eri et al., 1998).
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Peripheral nerve injury triggers TNFα, MCP-1, ILα, ILβ,
and IL6 expression in Schwann cells and they peak at
24 h following injury (Rotshenker, 2011). Increasing evidence
shows that there are remarkable similarities between inherited
peripheral neuropathies and peripheral nerve trauma in term
of inflammatory response although the former is chronic
and the latter is acute (Martini et al., 2013; Klein and
Martini, 2016). In pathological situations such as Charcot-
Marie-Tooth (CMT) disease, acute inflammatory demyelinating
polyneuropathy (AIDP), and chronic inflammatory demyeli-
nating polyneuropathy (CIDP), Schwann cells also release
pro-inflammatory cytokines and recruit macrophages to the
peripheral nerves. Macrophages are the major immune cells
to be found in the peripheral nerves of animal models for
CMT diseases (Fledrich et al., 2012; Martini et al., 2013). In
response to chemokines released by Schwann cells in CMT
animal models, macrophages enter into the peripheral nerves
and phagocytose myelin to leave the demyelinated axons intact
and, thus, they strongly contribute to the pathogenesis of CMT
disorders (Ip et al., 2006).
Investigations in human nerve biopsies have revealed that
abnormal macrophage recruitment plays a key role in the
demyelination process in neuropathies such as CMT, AIDP, and
CIDP diseases (Martini et al., 2013; Klein and Martini, 2016).
Inherited peripheral neuropathies in humans are still incurable
and lead to muscle wasting, sensory dysfunction and progressive
disability (Fledrich et al., 2012). As such, the development of
novel therapeutic approaches becomes important. In this study,
we show that VIP and PACAP treatment not only inhibits
TNFα, MCP-1, ILα, ILβ, and IL6 expression in Schwann cells
induced by Poly:IC and LPS stimulation but also significantly
reduced TNFα, MCP-1, ILα, ILβ, and IL6 expression in nerve
explants. Our findings from this study have indicated the
potential for using exogenous VIP and PACAP through VPAC1
and VPAC2 receptors to inhibit the release of pro-inflammatory
cytokines by Schwann cells in such pathological situations. Thus,
further investigation of VIP and PACAP immunomodulatory
function on CMT mouse models could potentially develop
VIP and PACAP as novel molecules for the treatment of
peripheral neuropathies.
We show here that up-regulated VIP and PACAP could act
on both Schwann cells and macrophages in the distal nerve
stump and potentially regulate peripheral nerve regeneration.
Although both VIP and PACAP were up-regulated in neurons
following peripheral nerve injury, PACAP reaches its peak
expression at day 2 while VIP reaches its peak expression at
day 7 (Armstrong et al., 2003; Navarro et al., 2007). Their
peak difference indicates that VIP and PACAP may execute
distinct function in the distal nerve stump at different time
points during regeneration. Our treatment with PAC1 specific
agonist significantly up-regulated IL6, ILβ and MCP-1 expression
in sciatic nerve explants (Figure 8B). This result indicated that
PACAP may have the ability to promote early pro-inflammatory
cytokine production in the sciatic nerve following injury.
However, activation of PAC1 has no effect on the release of pro-
inflammatory cytokine in cultured Schwann cells (Figure 7B),
indicating that PACAP may act on a different cell type in the
sciatic nerve explants and promote pro-inflammatory cytokine
release. About 8% cells in the peripheral nerves are known
to be resident macrophages and their activation contributes
significantly to the early release of pro-inflammatory cytokine
following peripheral nerve injury (Stierli et al., 2018; Zigmond
and Echevarria, 2019). We showed that macrophages in the
mouse sciatic nerve express PAC1 the receptor (Figure 5), thus,
PACAP peaking at day 2 following injury may have an important
function by acting on resident macrophages to promote early
pro-inflammatory cytokine production. In contrast, the peak
expression of VIP on day 7 following peripheral nerve injury
well matches with the time point of pro-inflammatory cytokine
down-regulation. Therefore, VIP could have more a important
function than PACAP in terms of the resolution of the distal
nerve inflammatory response.
Taken together, in this study, we showed that VPAC1,
VPAC2, and PAC1 are up-regulated in Schwann cells and
macrophages of the distal nerve stump after peripheral nerve
injury. Neuron secreted VIP and PACAP could bind to these
receptors on Schwann cells and macrophages in the distal
stump to execute distinct functions at different stages of
regeneration. In the early stage of peripheral nerve injury,
VIP and PACAP could balance pro-inflammatory cytokine
production and prevent unnecessary macrophage recruitment.
In the later stage of regeneration, VIP and PACAP may down-
regulate the expression of pro-inflammatory cytokines and
up-regulate the production of anti-inflammatory cytokines in
macrophages to trigger the macrophage stage transition and
eventually terminate the inflammatory response in the distal
nerve stump. In the later stages of peripheral nerve regeneration,
VIP and PACAP may also have important function in promoting
Schwann cell re-myelination.
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